Phase I study of pulsatile 3-day administration of afatinib (BIBW 2992) in combination with docetaxel in advanced solid tumors

Background A phase I study to assess the maximum tolerated dose (MTD) of a short course of afatinib in combination with docetaxel for the treatment of solid tumors. Methods Patients with advanced solid malignancies received docetaxel 75 mg/m(2) intravenously on day 1 and oral afatinib once daily on...

Descripción completa

Detalles Bibliográficos
Autores principales: Awada, A. H., Dumez, H., Hendlisz, A., Wolter, P., Besse-Hammer, T., Uttenreuther-Fischer, M., Stopfer, P., Fleischer, F., Piccart, M., Schöffski, P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2012
Materias:
Phase I Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3644400/
https://www.ncbi.nlm.nih.gov/pubmed/23161334
http://dx.doi.org/10.1007/s10637-012-9880-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3644400/
https://www.ncbi.nlm.nih.gov/pubmed/23161334
http://dx.doi.org/10.1007/s10637-012-9880-0

Ejemplares similares